Dublin, Feb. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Hemophilia Market (By Treatment Regimen, Type & Therapy): Insights & Forecast with Potential Impact of COVID-19 (2023-2027)" report has been added to ResearchAndMarkets.com's offering.
The global hemophilia market is anticipated to reach US$16.78 billion in 2027, growing at a CAGR of 5.80% during the period spanning 2023-2027.
The growth in the market has been driven by factors like increasing healthcare expenditure, surging identified hemophilia patient volume, increased focus on prophylactic treatment, rise in male population and favorable government initiatives. The market is expected to face certain challenges such as high cost of treatment and reluctance to switch to newer therapies.
To overcome these challenges, the market would witness some key trends like development of novel hemophilia treatments and rising popularity of gene therapy.
The global hemophilia market by treatment regimen can be segmented as follows: prophylaxis and on-demand. In 2022, the higher share was held by prophylaxis segment, followed by on-demand segment. The global hemophilia market by type can be segmented into the following: hemophilia A and hemophilia B, where hemophilia A held a larger share of the market in 2022. The global hemophilia market by therapy can be segmented as follows: replacement therapy and ITI therapy. The dominant share of the market in 2022 was held by replacement therapy segment.
The global hemophilia market by region can be segmented into the following regions: North America, Europe and Asia Pacific. In 2022, the dominant share of the market was held by North America, followed by Europe and Asia Pacific. The factors like rising prevalence of hemophilia, growing knowledge amongst individuals regarding different treatment methods and surging inclination towards prophylaxis treatment contributed towards growth in the North American market.
Market Dynamics
Growth Drivers
- Increased Focus on Prophylactic Treatment
- Increasing Diagnosis Rate
- Rise in Global Healthcare Expenditure
- Rise in Male Population
- Favourable Government Initiatives
Key Trends & Development
- Shifting Focus to Extended Half Life Therapies
- Development of Novel Hemophilia Treatments
- Popularity of Gene Therapy
Challenges
- High Cost of Treatment
- Reluctance to Switch to New Therapies
Scope of the report
- The report provides a comprehensive analysis of the global hemophilia market, segmented into hemophilia A and hemophilia B.
- The major regional markets North America, Europe and Asia Pacific with country analysis of the US have been analyzed.
- The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
- The competitive landscape of the market, along with the company profiles of leading players (Pfizer Inc., Bayer Group, Sanofi S.A., Takeda Pharmaceutical Company, Novo Nordisk and CSL Limited) are also presented in detail.
Key Target Audience
- Hemophilia Drugs Manufacturers
- API Suppliers
- End Users (Hospital, Medical Centers, Clinical Institutes)
- Healthcare Consulting Firms
- Investment Banks
- Government Bodies & Regulating Authorities
Key Topics Covered:
1. Market Overview
2. Impact of COVID-19
3. Global Market Analysis
4. Regional Market Analysis
4.1 North America
4.2 Europe
4.3 Asia Pacific
4.4 ROW
5. Market Dynamics
6. Competitive Landscape
6.1 Global Market
6.2 The US Market
6.3 Europe Market
7. Company Profiles
Companies Mentioned
- Pfizer Inc.
- Bayer Group
- Sanofi S.A.
- Takeda Pharmaceutical Company
- Novo Nordisk
- CSL Limited
For more information about this report visit https://www.researchandmarkets.com/r/4h5x6x-hemophilia?w=12
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
